1983年美国的Wolf等人证实了生物素酶缺乏可导致迟发型多羧酶缺乏症(MCD)。并称该病为生物素酶缺乏症。本病在出生后即出现酶活性异常,而临床症状出现时期及程度却各不相同。因此,若不能及时发现则可发生不可逆的脑组织障碍。但如能早期发现,本病是可以治疗的。目前,以美国为首的某些国家,开始了筛选测定血中生物素酶活性的方法。生物素酶的作用是使羧酶的辅酶即生物素从羧酶中游离出来,在体内生物素的再利用方面起着极为重要的作用。一般认为,如果生物素不能被再利用,仅依靠通常饮食摄取的生物 In 1983, Wolf et al. In the United States demonstrated that lack of biotinase can lead to delayed type polycarboxylase deficiency (MCD). And said the disease is biotinidase deficiency. The disease occurs after birth, abnormal enzyme activity, and clinical symptoms occur at different times and extent. Therefore, if not found in time can occur irreversible brain tissue disorders. However, if early detection, the disease can be treated. At present, some countries led by the United States have started screening methods for measuring the activity of the biotin in the blood. The role of the biotin enzyme is to make the coenzyme of the carboxylase biotin free from the carboxylase, which plays an extremely important role in the reutilization of biotin in the body. It is generally believed that if biotin can not be reused, it depends only on the creatures that are normally consumed